Advertisement

Topics

Psylin Neurosciences, Inc. Company Profile

06:26 EDT 24th September 2017 | BioPortfolio

Psylin Neurosciences, Inc. was formed in January, 2007 as a 50/50 joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. Psylin's mission is to pioneer the development of peptide therapeutics in neuropsychiatric disorders. Psylin has access to molecules in Amylin's PHORMOL library and to PsychoGenics' proprietary drug discovery technologies. Amylin's expertise in peptide biology, manufacturing and drug delivery, combined with PsychoGenics' expertise in preclinical neuropharmacology, provide Psylin with a unique drug discovery resource. Psylin has the right to develop a number of drug candidates in psychiatric disorders emerging from this collaboration.


News Articles [82 Associated News Articles listed on BioPortfolio]

ProMIS Neurosciences: ProMIS Neurosciences Independent Director Anthony J. Giovinazzo Recognized with Inaugural Bloom Burton Award for Innovation in Canadian Healthcare

ProMISTM Neurosciences, Inc. NEWS RELEASE TSX: PMN TORONTO, ONTARIO and CAMBRIDGE, MA - September 21, 2017 - ProMIS Neurosciences, Inc., a company focused on the discovery and development of preci...

ProMIS Neurosciences: ProMIS Neurosciences Completes First Closing of Private Placement

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, ONTARIO - August 9, 2017 - ProMIS Neurosciences Inc. ("ProMIS" or the "Company") (TSX:PMN; OTCPK:A...

ProMIS Neurosciences: ProMIS Neurosciences Increases Size of Private Placement to $6 Million

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, ONTARIO - August 2, 2017 - ProMIS Neurosciences Inc. ("ProMIS" or the "Company") (TSX:PMN; OTCPK:A...

ProMIS Neurosciences: ProMIS Neurosciences Announces CDN$3 Million Best-Efforts Private Placement

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, ON - July 20, 2017 - ProMIS Neurosciences Inc. ("ProMIS" or the "Company") (TSX:PMN; OTCPK:ARFX.F;...

ProMIS Neurosciences: ProMIS Neurosciences Appoints William C. Mobley to Scientific Advisory Board

TORONTO and CAMBRIDGE, Mass., June 06, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN), a biotechnology company focused on the discovery and development of precision treatments for n...

Minerva Neurosciences, Inc.: Minerva Neurosciences, Inc. to Offer Common Shares

WALTHAM, Mass., 2017-06-27 22:10 CEST (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 5,00...

ProMIS Neurosciences: ProMIS Neurosciences Announces Q1 2017 Annual Results

TORONTO, Ontario - May 9, 2017 - ProMIS Neurosciences, Inc. (TSX:PMN) ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative ...

ProMIS Neurosciences: ProMIS Neurosciences Announces Second Quarter 2017 Results

TORONTO and CAMBRIDGE, Mass., Aug. 11, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments f...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Myobloc [Solstice Neurosciences, LLC]

Myobloc (rimabotulinumtoxinB) Injection

PubMed Articles [121 Associated PubMed Articles listed on BioPortfolio]

The surge of predatory open-access in neurosciences and neurology.

Predatory open access is a controversial publishing business model that exploits the open-access system by charging publication fees in the absence of transparent editorial services. The credibility o...

NeurHistAlert 23.

End-of-Volume Editorial Board.

Clarification by Richard Leblanc.

Hippocampal Sclerosis in a Child with Multiple Neurocysticercosis.

Clinical Trials [8 Associated Clinical Trials listed on BioPortfolio]

Enhancing Social Interaction With an AlterEgo Artificial Agent

The objective of AlterEgo is the creation of an interactive cognitive architecture, implementable in various artificial agents, allowing a continuous interaction with patients suffering fr...

Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies

The project will improve scientific knowledge regarding a recent law applying potentially to every french driver. It will give for the first time an indication on the impact of alerting tr...

Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers

The development of a new automated method of measurement of the volume of the hippocampus allows confirming these results in patients presenting with pre-dementia AD, treated with donepezi...

Cohorts and Collections: Clinical and Genetic Study of Parkinson's Disease and Epilepsies

The DNA and Cell Bank of Instituts Federatifs de Recherche (IFR) of Neurosciences has been running for the last 15 years at the Institut National de la Santé Et de la Recherche Médicale ...

Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression

Major depressive disorder (MDD) is a common, recurrent, and frequent chronic disorder. Treatment is often challenging; an estimated 20-40% of patients do not benefit sufficiently from exis...

Companies [49 Associated Companies listed on BioPortfolio]

Psylin Neurosciences, Inc.

Psylin Neurosciences, Inc. was formed in January, 2007 as a 50/50 joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. Psylin's mission is to pioneer the...

Merz Neurosciences

Merz Neurosciences is a division of Merz North America, a specialty healthcare company that develops and commercializes treatment solutions in aesthetics, dermatology and neurosci...

Nautilus Neurosciences, Inc.

Nautilus Neurosciences, Inc. is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with medically relevant products and services ...

Ester Neurosciences Ltd

Ester Neurosciences Ltd. is a development stage biopharmaceutical company committed to the discovery and development of novel therapeutic products for the treatment of neurological disorders such as m...

Knopp Neurosciences Inc.

Knopp Neurosciences, based in Pittsburgh, PA, USA, is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through inn...

More Information about "Psylin Neurosciences, Inc." on BioPortfolio

We have published hundreds of Psylin Neurosciences, Inc. news stories on BioPortfolio along with dozens of Psylin Neurosciences, Inc. Clinical Trials and PubMed Articles about Psylin Neurosciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Psylin Neurosciences, Inc. Companies in our database. You can also find out about relevant Psylin Neurosciences, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record